Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Current Patient Education Video Series Navigation
dbrock
Many series of Patient Education materials can be viewed in the EDUCATE drop-down in the navigation bar!
Did you know that current GRACE programs can be accessed under our EDUCATE navigation bar?
If you want to keep up on what content GRACE is producing, or if there is a specific program you are interested in seeing throughout the years, there are many ways to find that information. One of the best tools is the navigation drop-down under EDUCATE.
So much important information lives on the GRACE website, we are often finding that keeping everyone up to date on what information is available can be a daunting task! The list of programs under the EDUCATE dropdown will continue to grow and keep the most up-to-date, edited information available for our community.
Another excellent place to find the newest GRACE information is our YouTube channel, found at https://www.youtube.com/GRACE4cancerinfo. We also are always happy to answer a question through our Forums, available at https://cancergrace.org/forums.
Last but not least, you can search for information on the GRACE site via the search box in the upper right corner!
And of course for questions or concerns, please contact us through our contact form at https://cancergrace.org/contact.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.